CA3091792A1 - Methods of use for trisubstituted benzotriazole derivatives - Google Patents

Methods of use for trisubstituted benzotriazole derivatives Download PDF

Info

Publication number
CA3091792A1
CA3091792A1 CA3091792A CA3091792A CA3091792A1 CA 3091792 A1 CA3091792 A1 CA 3091792A1 CA 3091792 A CA3091792 A CA 3091792A CA 3091792 A CA3091792 A CA 3091792A CA 3091792 A1 CA3091792 A1 CA 3091792A1
Authority
CA
Canada
Prior art keywords
cancer
compound
pharmaceutically acceptable
cell lymphoma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3091792A
Other languages
English (en)
French (fr)
Inventor
Danielle ULANET
Sung Eun CHOE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CA3091792A1 publication Critical patent/CA3091792A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3091792A 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives Pending CA3091792A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2018/018679 2018-02-20
US2018018679 2018-02-20
PCT/US2019/018472 WO2019164794A1 (en) 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives

Publications (1)

Publication Number Publication Date
CA3091792A1 true CA3091792A1 (en) 2019-08-29

Family

ID=61692059

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3091792A Pending CA3091792A1 (en) 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives

Country Status (13)

Country Link
US (2) US11717512B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755324B1 (cg-RX-API-DMAC7.html)
JP (2) JP7434185B2 (cg-RX-API-DMAC7.html)
KR (1) KR102861339B1 (cg-RX-API-DMAC7.html)
CN (1) CN111757731B (cg-RX-API-DMAC7.html)
AU (1) AU2019223906B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016929A8 (cg-RX-API-DMAC7.html)
CA (1) CA3091792A1 (cg-RX-API-DMAC7.html)
ES (1) ES3038736T3 (cg-RX-API-DMAC7.html)
MA (1) MA51897A (cg-RX-API-DMAC7.html)
MX (1) MX2020008678A (cg-RX-API-DMAC7.html)
TW (1) TWI818954B (cg-RX-API-DMAC7.html)
WO (1) WO2019164794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3091792A1 (en) * 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
BR112021012305A2 (pt) 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas
CN111662872A (zh) * 2020-05-06 2020-09-15 西南医科大学附属医院 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法
US20230285364A1 (en) * 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9708620A (es) 1995-05-10 1998-02-28 Pfizer Combinacion de metotrexate y tenidap para el tratamiento de artritis reumatoide.
AU7622000A (en) 1999-10-01 2001-05-10 Institute Of Molecular And Cell Biology Compounds for the treatment of viral-mediated diseases
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
NZ588896A (en) * 2004-08-25 2012-05-25 Targegen Inc Heterocyclic compounds and methods of use
MX2007003375A (es) 2004-09-22 2007-05-07 Janssen Pharmaceutica Nv Inhibidores de la interaccion entre mdm2 y p53.
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
DE102005049953A1 (de) 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
KR101177729B1 (ko) 2006-09-08 2012-09-07 에프. 호프만-라 로슈 아게 벤조트리아졸 키나아제 조절제
WO2010081898A1 (en) 2009-01-19 2010-07-22 Neurosearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
US9316632B2 (en) 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
SG174125A1 (en) 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
WO2013049112A1 (en) 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
CN103965133B (zh) 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
ES2694829T3 (es) * 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6629840B2 (ja) 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
EP3344243B1 (en) * 2015-09-01 2020-12-09 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
MX2018008169A (es) 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
EP3858361B1 (en) 2018-09-28 2025-10-08 FUJIFILM Corporation Antitumor agent containing cytarabine, antitumor effect enhancer used in combination with cytarabine, antitumor kit, and antitumor agent used in combination with cytarabine
WO2020109625A1 (en) 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
BR112021012305A2 (pt) 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas
EP4034084B1 (en) 2019-09-27 2025-11-05 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
US20230285364A1 (en) 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Also Published As

Publication number Publication date
KR20200123137A (ko) 2020-10-28
US11717512B2 (en) 2023-08-08
WO2019164794A1 (en) 2019-08-29
AU2019223906B2 (en) 2024-11-21
EP3755324A1 (en) 2020-12-30
EP3755324C0 (en) 2025-07-30
BR112020016929A2 (pt) 2020-12-15
MA51897A (fr) 2020-12-30
US12290508B2 (en) 2025-05-06
AU2019223906A1 (en) 2020-09-10
JP7434185B2 (ja) 2024-02-20
CN111757731A (zh) 2020-10-09
ES3038736T3 (en) 2025-10-14
TW201938543A (zh) 2019-10-01
CN111757731B (zh) 2024-06-25
KR102861339B1 (ko) 2025-09-19
JP2021514395A (ja) 2021-06-10
EP3755324B1 (en) 2025-07-30
JP2023109974A (ja) 2023-08-08
US20240148697A1 (en) 2024-05-09
TWI818954B (zh) 2023-10-21
US20210113531A1 (en) 2021-04-22
MX2020008678A (es) 2020-09-25
BR112020016929A8 (pt) 2022-06-28

Similar Documents

Publication Publication Date Title
US12290508B2 (en) Methods of use for trisubstituted benzotriazole derivatives
CN104271159B (zh) 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
JP6855243B2 (ja) 癌治療のためのアピリモド(apilimod)組成物
US9782427B2 (en) Methods for treating cancer using TOR kinase inhibitor combination therapy
CN105050623B (zh) Pi3k抑制剂和c-met抑制剂的组合
AU2016213972A1 (en) Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer
CN110536703A (zh) 使用抗axl抗体-药物缀合物的组合疗法
JP2023504046A (ja) ジアリール大環状化合物を含む併用療法
RU2657783C2 (ru) Комбинированная терапия с использованием азабициклосоединения для ракового заболевания
CN105338980A (zh) 药物组合
KR20230074533A (ko) Csf1r 키나아제 억제제 및 이의 용도
JP7547360B2 (ja) Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法
AU2014279721A1 (en) Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent
WO2018064851A1 (zh) 低剂量西地那非作为抗肿瘤药物的应用
EP4656193A1 (en) Pharmaceutical composition for treating tumors
HK40043674B (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
HK40043674A (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
CN117794523A (zh) 使用parp抑制剂和plk1抑制剂的癌症治疗
CN116546986A (zh) Alk-5抑制剂及其用途
US20230090742A1 (en) Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors
WO2025070603A1 (ja) 血液がんの新規併用療法
HK1258689B (en) Aminothiazole compounds and use thereof
HK1258689A1 (zh) 氨基噻唑化合物及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250210

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250210

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250228

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250630

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251203